Targeting alpha-synuclein in the gut may slow down Parkinson's disease

November 13, 2019

Amsterdam, NL, November 13, 2019 - Aggregates of the protein alpha-synuclein arising in the gut may play a key role in the development of Parkinson's disease (PD). Investigators are testing the hypothesis that by targeting the enteric nervous system with a compound that can inhibit the intracellular aggregation of alpha-synuclein, they can restore enteric functioning in the short term, and possibly slow the progressive deterioration of the central nervous system in the long term. They review results to date in the Journal of Parkinson's Disease.

"There is growing evidence that PD may start off in the gut," explained senior author Michael Zasloff, MD, PhD, Enterin Inc., Philadelphia, PA, and MedStar Georgetown Transplant Institute, Georgetown University Medical Center, Washington, DC. "The concept is that aggregates of the protein alpha-synuclein, thought to play a key role in the disease, arise within the enteric nervous system (ENS) and travel up the peripheral nerves to the central nervous system (CNS) where they ultimately cause inflammation and destruction of parts of the brain. Targeting the formation of alpha-synuclein aggregates in the ENS may therefore slow the progression of the disease."

Alpha-synuclein is one of the defensive proteins produced by enteric nerves when they encounter infections. In children with acute bacterial GI infections, for example, intestinal nerves produce alpha-synuclein. In children who have undergone intestinal transplants and who are prone to GI infections, investigators have shown that enteric neurons start making alpha-synuclein at the time of acute viral infections, and this outlasts the infection by many months, protecting nerve cells for prolonged periods of time. Within a nerve cell, alpha-synuclein could envelop invading viruses and disrupt their replication. It could also attach itself to small vesicles containing neurotransmitters and be released from the nerve cell hitching a ride with them. Once on the outside, it can attract protective immune cells from surrounding tissues.

"Recent data from our laboratory and others demonstrate that alpha-synuclein is induced in the setting of viral and bacterial infection and serves an immune function by protecting the ENS, by alerting the adaptive immune system and through pre-emptive defense of the CNS in advance of the infectious agent," noted first author Denise Barbut, MD, FRCP, Enterin Inc., Philadelphia, PA. "In the setting of chronic GI infections or impaired intestinal barrier function, when the expression of alpha-synuclein exceeds its clearance, neurotoxic aggregates of alpha-synuclein form damaging aggregates in the ENS and traffic to the CNS."

To determine whether targeting alpha-synuclein within enteric neurons might help patients with PD, Dr. Barbut, Dr. Zasloff and colleagues are currently conducting clinical trials with a compound called ENT-01 (Enterin Inc.). ENT-01 is a synthetic derivative of squalamine, a compound originally isolated from dogfish bile by Dr. Zasloff. It displaces alpha-synuclein from nerve cell membranes and restores the normal electrical activity of enteric neurons. Investigators completed a 50-patient Phase 2a study (RASMET) in patients with PD in 2018, which corrected constipation in more than 80% of participants, with the dose titrated up for each patient until a response was obtained. Constipation is a common symptom of PD.

According to Dr. Barbut, "The RASMET study demonstrated that the ENS is not irreversibly damaged in patients with PD, despite the longstanding constipation that might suggest otherwise. We believe that this is the first demonstration of the reversal of a neurodegenerative process in humans." Beyond the bowel symptoms, possible benefits were also observed in motor and non-motor symptoms such as hallucinations, depression and cognitive function.

A 110-patient double-blind, placebo-controlled Phase 2b trial (KARMET) evaluating the effect of oral ENT-01 tablets on constipation and neurologic symptoms is currently being conducted.

PD is a slowly progressive disorder that affects movement, muscle control and balance. It is the second most common age-related neurodegenerative disorder affecting about 3% of the population by the age of 65 and up to 5% of individuals over 85 years of age.
-end-


IOS Press

Related Central Nervous System Articles from Brightsurf:

Chikungunya may affect central nervous system as well as joints and lungs
Investigation conducted by international group of researchers showed that chikungunya virus can cause neurological infections.

IL-21 protein a key part of immune response to central nervous system infections
esearchers at Penn State College of Medicine now better understand the role of a protein, interleukin-21 (IL-21), in the immune system response to infections in the nervous system.

COVID-19 may attack patients' central nervous system
''There may be more central nervous system penetration of the virus than we think based on the prevalence of olfaction-associated depressed mood and anxiety and this really opens up doors for future investigations to look at how the virus may interact with the central nervous system,'' explains Ahmad Sedaghat, MD, PhD.

Lifting weights makes your nervous system stronger, too
Gym-goers may get frustrated when they don't see results from weightlifting right away, but their efforts are not in vain: the first few weeks of training strengthen the nervous system, not muscles.

COVID-19 threatens the entire nervous system
A new review of neurological symptoms of COVID-19 patients in current scientific literature reveals the disease poses a global threat to the entire nervous system.

Zika combats advanced-stage central nervous system tumors in dogs
The viral therapy was tested in three elderly animals with spontaneous brain tumors by a group affiliated with the FAPESP-funded Human Genome and Stem Cell Research Center.

Fewer scars in the central nervous system
Researchers have discovered the influence of the coagulation factor fibrinogen on the damaged brain.

Mayo Clinic discovers a molecular switch for repairing central nervous system disorders
A molecular switch has the ability to turn on a substance in animals that repairs neurological damage in disorders such as multiple sclerosis (MS), Mayo Clinic researchers discovered.

Discovery concerning the nervous system overturns a previous theory
It appears that when our nervous system is developing, only the most viable neurons survive, while immature neurons are weeded out and die.

Nanocapsule reaches cancer that has spread to central nervous system in mice
Researchers developed a drug delivery system that can break through the blood-brain barrier in mice.

Read More: Central Nervous System News and Central Nervous System Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.